Increased headcount should allow the FDA to up the number of approvals – but not quite yet.
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.
The nightmare on the public markets is not confined to the bigger groups.
The worst half-year period for a decade leaves the biggest medical device companies half a trillion dollars poorer.
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.
The gloomy climate for biotech is now taking its toll on private companies too.